{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:14Z","timestamp":1790743334481,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23790187"],"award-info":[{"award-number":["23790187"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25460190"],"award-info":[{"award-number":["25460190"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25460652"],"award-info":[{"award-number":["25460652"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H05114"],"award-info":[{"award-number":["16H05114"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Foundation for Pharmaceutical Sciences"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bcp.2017.08.016","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T07:32:05Z","timestamp":1503559925000},"page":"192-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP\/PI3K\/PKC\/PKA\/NF-\u03baB signaling pathway in secondary hyperparathyroidism"],"prefix":"10.1016","volume":"145","author":[{"given":"Hiroshi","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusei","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiya","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshiro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Jingami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Komaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2017.08.016_b0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/clpt.2008.208","article-title":"Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications","volume":"85","author":"Zhang","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.V122326","article-title":"Downregulation of hepatic cytochrome P450 in chronic renal failure","volume":"12","author":"Leblond","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.bcp.2017.08.016_b0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0009-9236(03)00056-0","article-title":"Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease","volume":"73","author":"Dowling","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2017.08.016_b0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0091270003262952","article-title":"Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment","volume":"44","author":"Shi","year":"2004","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2017.08.016_b0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/bmb.2006.49403402066","article-title":"Cytochrome P450 enzymes in drug metabolism and chemical toxicology: an introduction","volume":"34","author":"Furge","year":"2006","journal-title":"Biochem. Mol. Biol. Educ."},{"issue":"1","key":"10.1016\/j.bcp.2017.08.016_b0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome p450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2017.08.016_b0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1211\/jpp.62.01.0015","article-title":"Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro","volume":"62","author":"Tsujimoto","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2017.08.016_b0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.2009.247","article-title":"Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease","volume":"87","author":"Sun","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2017.08.016_b0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ki.1995.292","article-title":"The pathogenesis of parathyroid gland hyperplasia in chronic renal failure","volume":"48","author":"Dr\u00fceke","year":"1995","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0272-6386(12)80977-2","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"23","author":"Slatopolsky","year":"1994","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.bcp.2017.08.016_b0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am. J. Nephrol."},{"issue":"5","key":"10.1016\/j.bcp.2017.08.016_b0065","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"E.U.T.W.G. (EUTox), Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.bcp.2017.08.016_b0070","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1359\/jbmr.2000.15.6.1033","article-title":"Nuclear localization of the type 1 PTH\/PTHrP receptor in rat tissues","volume":"15","author":"Watson","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"Kir","year":"2016","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.bcp.2017.08.016_b0080","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1172\/JCI118657","article-title":"Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone","volume":"97","author":"Klin","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bcp.2017.08.016_b0085","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","article-title":"Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure","volume":"17","author":"Michaud","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.bcp.2017.08.016_b0090","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1523-1755.2005.00505.x","article-title":"Role of membrane microdomains in PTH-mediated down-regulation of NaPi-IIa in opossum kidney cells","volume":"68","author":"Nashiki","year":"2005","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.bcp.2017.08.016_b0095","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00100.2006","article-title":"Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter","volume":"292","author":"Segawa","year":"2007","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2017.08.016_b0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.kint.2016.09.041","article-title":"Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism","volume":"91","author":"Sugimoto","year":"2017","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.bcp.2017.08.016_b0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/ki.2012.448","article-title":"p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase","volume":"83","author":"Watanabe","year":"2013","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.bcp.2017.08.016_b0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/dmd.112.048744","article-title":"Carbon monoxide-bound red blood cells protect red blood cell transfusion-induced hepatic cytochrome P450 impairment in hemorrhagic-shock rats","volume":"41","author":"Ogaki","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2017.08.016_b0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2005.06.019","article-title":"Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism","volume":"109","author":"Nagano","year":"2006","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0120","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2017.08.016_b0125","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/ki.2008.407","article-title":"Cinacalcet suppresses calcification of the aorta and heart in uremic rats","volume":"74","author":"Kawata","year":"2008","journal-title":"Kidney Int."},{"issue":"24","key":"10.1016\/j.bcp.2017.08.016_b0130","doi-asserted-by":"crossref","first-page":"16741","DOI":"10.1074\/jbc.274.24.16741","article-title":"Negative regulation of the forkhead transcription factor FKHR by Akt","volume":"274","author":"Tang","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2017.08.016_b0135","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1517\/17425250903012360","article-title":"Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression","volume":"5","author":"Pondugula","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"26","key":"10.1016\/j.bcp.2017.08.016_b0140","doi-asserted-by":"crossref","first-page":"17882","DOI":"10.1074\/jbc.M601302200","article-title":"Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents","volume":"281","author":"Gu","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0014-5793(99)01370-8","article-title":"Activation of NF-kappaB in human osteoblasts by stimulators of bone resorption","volume":"460","author":"Ali","year":"1999","journal-title":"FEBS Lett."},{"issue":"31","key":"10.1016\/j.bcp.2017.08.016_b0150","doi-asserted-by":"crossref","first-page":"28109","DOI":"10.1074\/jbc.M111013200","article-title":"Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells","volume":"277","author":"Guill\u00e9n","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2017.08.016_b0155","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1074\/jbc.M807426200","article-title":"Cyclic AMP-dependent protein kinase signaling modulates pregnane x receptor activity in a species-specific manner","volume":"284","author":"Lichti-Kaiser","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.104.076331","article-title":"Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway","volume":"312","author":"Ding","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2017.08.016_b0165","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bcp.2004.11.025","article-title":"Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C","volume":"69","author":"Ding","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2017.08.016_b0170","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/ATVBAHA.114.303637","article-title":"Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease","volume":"34","author":"Goettsch","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2017.08.016_b0175","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1074\/jbc.M109.051219","article-title":"Phosphorylation of Thr-516 and Ser-520 in the kinase activation loop of MEKK3 is required for lysophosphatidic acid-mediated optimal IkappaB kinase beta (IKKbeta)\/nuclear factor-kappaB (NF-kappaB) activation","volume":"285","author":"Sun","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2017.08.016_b0180","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1096\/fj.11-184861","article-title":"Response of chondrocytes to shear stress: antagonistic effects of the binding partners Toll-like receptor 4 and caveolin-1","volume":"25","author":"Wang","year":"2011","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.bcp.2017.08.016_b0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bbamcr.2009.11.011","article-title":"PTH inactivates the AKT survival pathway in the colonic cell line Caco-2","volume":"1803","author":"Calvo","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pharmthera.2009.10.011","article-title":"Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information","volume":"125","author":"Hisaka","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2017.08.016_b0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-9556(24)15271-3","article-title":"Molecular and physical mechanisms of first-pass extraction","volume":"27","author":"Hall","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.bcp.2017.08.016_b0200","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1211\/0022357001777676","article-title":"Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction","volume":"52","author":"Okabe","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2017.08.016_b0205","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/j.transproceed.2007.07.088","article-title":"Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report","volume":"39","author":"Maass","year":"2007","journal-title":"Transpl. Proc."},{"issue":"9","key":"10.1016\/j.bcp.2017.08.016_b0210","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.amjmed.2005.09.041","article-title":"Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient","volume":"120","author":"Peng","year":"2007","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2017.08.016_b0215","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/0091270007304103","article-title":"Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies","volume":"47","author":"Nakashima","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2017.08.016_b0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.bcp.2017.08.016_b0225","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM)","volume":"10","author":"Wetmore","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217305439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217305439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T01:13:13Z","timestamp":1750813993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217305439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":45,"alternative-id":["S0006295217305439"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.08.016","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP\/PI3K\/PKC\/PKA\/NF-\u03baB signaling pathway in secondary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}